Mostrar registro simples

dc.date.accessioned2020-12-18T19:34:30Z
dc.date.available2020-12-18T19:34:30Z
dc.date.issued2020-12-18
dc.identifier.urihttps://iris.paho.org/handle/10665.2/52719en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12663/1159
dc.description.abstractSummary of rapid systematic reviews, from the 8th edition of the document and above.en_US
dc.languageEnglishen_US
dc.subjectCOVID-19en_US
dc.subjectCoronavirusen_US
dc.subjectInfecitous Diseasesen_US
dc.subjectSystematic Reviewsen_US
dc.subjectTherapeuticsen_US
dc.subjectMeplazumaben_US
dc.subjectIvermectinen_US
dc.subjectSiltuximaben_US
dc.subjectDanopreviren_US
dc.subjectTocilizumaben_US
dc.subjectFavipiraviren_US
dc.subjectDarunaviren_US
dc.subjectNelfinaviren_US
dc.subjectRemdesiviren_US
dc.subjectCloroquineen_US
dc.subjectHydroxychloroquineen_US
dc.subjectConvalescent Plasmaen_US
dc.subjectCorticosteroidsen_US
dc.subjectUmifenoviren_US
dc.subjectLopinaviren_US
dc.subjectRitonaviren_US
dc.titleOngoing Living Update of Potential COVID-19 Therapeutics Options: Summary of Evidence. Rapid Reviewen_US
eihealth.countryRegional, Americas (PAHO/OPS)en_US
eihealth.categoryCandidate therapeutics RDen_US
eihealth.typeWHO / PAHO Guidanceen_US
eihealth.maincategorySave Lives / Salvar Vidasen_US
dc.contributor.corporatenamePan American Health Organizationen_US


Arquivos deste item

ArquivosTamanhoFormatoVisualização

Não existem arquivos associados a este item.

Este item aparece na(s) seguinte(s) coleção(s)

Mostrar registro simples